 |
27 Products |  |
63 Diseases | | 27 Products |
|
80 Trials |  |
3278 News |  |
| «12...345678910111213...4849» |
- Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Erythrodermic Psoriasis: monocentric clinical experience with brodalumab () - Jul 3, 2023 - Abstract #WCD2023WCD_6798;
One of them has to stop therapy for an adverse event not correlated to treatment; he quickly suffers an erythrodermic relapse with a new complete remission after brodalumab resumption in similar time of bio-na
- Efficacy of anti-IL17 treatment in patients with moderate-severe plaque psoriasis who had failed IL-23 inhibitors () - Jul 3, 2023 - Abstract #WCD2023WCD_6789;
One of them has to stop therapy for an adverse event not correlated to treatment; he quickly suffers an erythrodermic relapse with a new complete remission after brodalumab resumption in similar time of bio-na First two patients prior to switch were receiving Risankizumab while last three were receiving Guselkumab for 7, 10, 5, 5 and 9 months respectively...First three patients switched to Brodalumab while later two to ixekizumab...Therefore we conclude that when patients fail to respond to an IL-23 antagonist, the IL-23/IL-17 axis is not
- Discontinuation rates of biologics in patients with psoriasis: 1 year (interim) follow-up of the Psoriasis Study of Health Outcomes (PSoHO) () - Jul 3, 2023 - Abstract #WCD2023WCD_6776;
Analyses are presented by cohort (anti-IL-17A (ixekizumab, secukinumab) and other biologics (adalimumab, brodalumab, certolizumab, etanercept, guselkumab, infliximab, risankizumab, and ustekinumab)) and by individual biologic. These real-world data from PSoHO show lower rates of drug discontinuation in patients with psoriasis treated with anti-IL-17A compared to a cohort including all other biologics collectively
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin, Cosentyx (secukinumab) / Novartis
Comparison among Brodalumab, Secukinumab and Ixekizumab efficacy: a real life experience on -638 psoriasis patients () - Jul 3, 2023 - Abstract #WCD2023WCD_6760;
Brodalumab and Ixekizumab appear superior to Secuckinumab in efficacy, without excess side effects or treatment discontinuation. The finding is consistent with the spurious comparisons that can be performed between the various registrational studies and single-drug real-life studies
- Desonate (desonide gel) / LEO Pharma
Comparative Study on the Efficacy of Desonide 0.05% scalp lotion versus CO2 cooling spray versus CO2 cooling spray with Exosome serum on Seborrheic Dermatitis: A Randomized Controlled trial () - Jul 3, 2023 - Abstract #WCD2023WCD_6574;
The finding is consistent with the spurious comparisons that can be performed between the various registrational studies and single-drug real-life studies CO2 cooling spray and CO2 cooling spray with exosome may be an alternative in the management of seborrheic dermatitis as compared to corticosteroid scalp lotion.
- Desonate (desonide gel) / LEO Pharma
Beyond steroids and calcineurins; topical epigallocatechin-gallate and CBD shampoo alternatives for resistant alopecia areata totalis () - Jul 3, 2023 - Abstract #WCD2023WCD_5765;
BACKGROUND: A 3-year-old female with no significant medical history presents with one year of alopecia areata totalis treated with several dermatologists with: multiple hair shampoos, topical minoxidil (5%), topical tacrolimus (0.3%), systemic (prednisolone), and topical steroids without improvement...We started treatment with CBD + nanoxidil shampoo daily (Revita-CBD, DS-laboratories), topical nanoxidil (Spectral DNC-L, DS laboratories) in the morning; occlusive desonide (Desowen, Galderma laboratories)by night 3 days a week and tacrolimus 0.3% (Traderma, Advaita laboratories) in the morning and the days without desonide, red light therapy (Kabel device, Sesderma laboratories) 3 days a week...Skin Appendage Disord. 2020 Nov;6(6):355-361
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study () - Jul 3, 2023 - Abstract #WCD2023WCD_5007;
Tralokinumab can be effective and safe in short-term improvement of symptoms in AD patients unresponsive to other systemic treatments, including dupilumab. A clinical response was obtained in patients presenting AD phenotypes particularly resistant to other conventional treatments, such as hand eczema, PN-like lesions, and portrait dermatitis
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Quality of life in atopic dermatitis and tralokinumab: a real life experience () - Jul 3, 2023 - Abstract #WCD2023WCD_4988;
Data highlight the drastic improvement of the quality of life of our patients during treatment, starting as early as the first month, and continuing over the long term . As our patients said
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron, Rinvoq (upadacitinib) / AbbVie
Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis () - Jul 3, 2023 - Abstract #WCD2023WCD_4935;
KEY MESSAGES: Despite the significant increase in possible systemic therapies for AD, a "multi-failure" patient population is emerging. Treatment of this population is still an unmet need
- Desonate (desonide gel) / LEO Pharma
Efficacy And Tolerability Of A Skin Care Regimen To Reduce Symptoms Of Atopic Dermatitis And To Prolong Flare-Up Free Phase In Babies And Kids. () - Jul 3, 2023 - Abstract #WCD2023WCD_4931;
Acute skin care formulations contaning Emollients PLUS Licochalcone A and Menthoxypropanediol can significantly support atopic skin during a flare-up, while daily care with Emollient plus Licochalcone A, Ceramides and Omega 3&6 can create a stable skin condition. All formulations are very tolerable for babies and kids, have shown to provide clinical efficacy and offer alternatives in the Atopic Dermatitis management
- Comparison of patient's profile initiating anticytokines and JAK inhibitors for atopic dermatitis in the OMCCI cohort () - Jul 3, 2023 - Abstract #WCD2023WCD_4905;
JAKi were initiated in younger patients This can be explained by the safety profile of JAKi. Revision process of JAKi
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca, Dupixent (dupilumab) / Sanofi, Regeneron
Comparison of different skin care regimens for patients with moderate to severe atopic dermatitis in addition to systemic treatment: results of a multicenter randomized controlled trial () - Jul 3, 2023 - Abstract #WCD2023WCD_4904;
In patients with moderate to severe AD receiving systemic treatment, additional treatment with Emollient+ significantly improves pruritus and quality of life aspects compared to routine treatment with commercial emollients. In addition, patients under Emollient+ regimen used less emollient balm compared to control group
- Dovonex (calcipotriol) / LEO Pharma, Novartis
308-nm excimer lamp ameliorates MC903?induced atopic dermatitis with a reduction of epidermal nerve fibers and thymic stromal lymphopoietin mRNA levels () - Jul 3, 2023 - Abstract #WCD2023WCD_4862;
In addition, irradiation of excimer lamp reduced mRNA expression of thymic stromal lymphopoietin (TSLP) in the skin on day 4. CONCLUSIONS Irradiation of excimer lamp ameliorated MC903-induced AD-like dermatitis with a reduction of epidermal nerve fibers and TSLP mRNA levels.
- Desonate (desonide gel) / LEO Pharma, Tetralysal (lymecycline) / Galderma
Severe papulopustular rosacea with demodicosis in a 47-year-old Filipino female: A case report () - Jul 3, 2023 - Abstract #WCD2023WCD_4575;
Due to the persistence of centrofacial erythema, papules and pustules, the patient was given prednisone 10mg once a day for 1 month and low dose isotretinoin 10mg once a day for 8 months which resulted in significant decrease in erythema and number of existing lesions...Gentle skin care measures, sunscreen, metronidazole 0.75% cream once a day, and desonide 0.05% cream twice a day for 1 week in cases of acute flares were maintained during the treatment course. KEY MESSAGE: An armamentarium of topical and oral antibiotics, corticosteroids, isotretinoin and non-ablative long-pulsed Nd:YAG 1064 nm laser showed significant improvement in the inflammatory papules, pustules, and centrofacial erythema of rosacea and proves to be beneficial in the maintenance of its long-term remission
- Desonate (desonide gel) / LEO Pharma
Acne Agminata In Disguise: A Case Report () - Jul 3, 2023 - Abstract #WCD2023WCD_4462;
KEY MESSAGE: An armamentarium of topical and oral antibiotics, corticosteroids, isotretinoin and non-ablative long-pulsed Nd:YAG 1064 nm laser showed significant improvement in the inflammatory papules, pustules, and centrofacial erythema of rosacea and proves to be beneficial in the maintenance of its long-term remission She was treated with oral Tetracycline hydrochloride and topical desonide 0.05% cream in perioral area...Patient was started on oral Dapsone (as patient had earlier not responded to oral tetracycline) and topical moisturiser...KEY MESSAGE: Thus, every case of acne that doesn
- Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Successful treatment of plaques psoriasis with brodalumab in patients with previous IL-23 antagonist failure: a report of six cases. () - Jul 3, 2023 - Abstract #WCD2023WCD_4273;
Our data describe the first real-world experience of brodalumab treatment when previous biologic therapies have failed in patients with moderate-to-severe plaque psoriasis. These case reports show that switch to brodalumab may be effective after IL- 23 inhibitor failure
- Dovonex (calcipotriol) / LEO Pharma, Novartis
Discovering and controlling immunopathogenic mediators inducing allergic itching () - Jul 3, 2023 - Abstract #WCD2023WCD_4239;
We applied calcipotriol (MC903), a low-calcium analog of vitamin D3, and ovalbumin (OVA) allergen on the ears of mice to induce pruritus associated with allergic inflammatory changes...The datasets of transcriptomic analysis of patients with atopic dermatitis found on the Gene Expression Omnibus revealed an increase of the specific gens observed in the mice skin lesion. In summary, our findings suggest that targeting immunopathogenic mediators could be a promising therapeutic strategy for the management of pruritus
- Dovonex (calcipotriol) / LEO Pharma, Novartis
The exopolysaccharide secreted by Roseomonas mucosa DL-1, a new microbiome treatment design for Atopic dermatitis () - Jul 3, 2023 - Abstract #WCD2023WCD_4144;
A mouse AD model that was induced by MC903, and treated by DL-1 and DL-EPS through topic application... The exopolysaccharide secreted by the skin commensal DL-1 play a key role in improving AD skin lesions, which may provide new treatment option for AD.
- Dovonex (calcipotriol) / LEO Pharma, Novartis
TET2 affect epidermal barrier homeostasis and regulates type 2 inflammation in atopic dermatitis () - Jul 3, 2023 - Abstract #WCD2023WCD_3870;
MATERIALS AND To explore the role of epidermal TET2 in AD pathogenic mechanisms, we collected tissues from AD patients and constructed MC903-AD mouse model using TET CKO (K14cre; TET2flox/flox) mice... Our study showed that epidermal TET2 is involved in the regulation the epidermal barrier homeostasis and influenced the release of type 2 cytokines in AD, which highlight the role of epigenetic regulation in AD.
- Dovonex (calcipotriol) / LEO Pharma, Novartis
Mast cell MRGPRX2/MrgprB2 activation promotes inflammation reaction in atopic dermatitis () - Jul 3, 2023 - Abstract #WCD2023WCD_3861;
MATERIALS AND Wild type (WT) and MrgprB2 knockout (MrgprB2-/-) mice were used to construct calcipotriol (MC903) AD mouse model, and H&E staining, immunofluorescent staining were used to show pathological changes and MCs activation... Our study clarified that MRGPRX2-mediated MC activation promotes AD inflammatory reaction by release tryptase.
- Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
First audit of tralokinumab treatment in real-world biologic-experienced cohort in the UK () - Jul 3, 2023 - Abstract #WCD2023WCD_3857;
Limitations include the small n number, hard-to-treat nature of the EUS cohort, and heterogeneity of clinical outcome reporting. Further work to determine real world experience in biologic-na
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
Preclinical, Journal: Epidermal Loss of ROR? Enhances Skin Inflammation in a MC903-Induced Mouse Model of Atopic Dermatitis. (Pubmed Central) - Jul 2, 2023
Our results substantiate the importance of epidermal ROR? in partially suppressing AD development by maintaining normal keratinocyte differentiation and skin barrier function.
- | Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal: Tralokinumab in elderly atopic dermatitis. (Pubmed Central) - Jun 30, 2023
in partially suppressing AD development by maintaining normal keratinocyte differentiation and skin barrier function. No abstract available
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Retrospective data, Journal, Real-world evidence, Real-world: Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis. (Pubmed Central) - Jun 28, 2023
Brodalumab was effective against psoriasis and psoriatic arthritis in a real-world setting. The drug survival was lower than reported in other real-world settings.
- |||||| temtokibart (LEO 138559) / LEO Pharma
New P2 trial, New P2b trial: A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Jun 28, 2023
P2b, N=250, Not yet recruiting, Sponsor: LEO Pharma
- |||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly, Dupixent (dupilumab) / Sanofi, Regeneron
Clinical: Apogee engineers drugs w/ longer half-lives. In #atopicdermatitis, blockbuster @Sanofi & @RegeneronPharma med #Dupixent, @LEOHealthySkin's #Adbry & @EliLillyandCo's experimental #lebrikizumab are dosed every 2-4 weeks. $APGE's goal is 2-3 month maintenance dosing. $SNY $REGN $LLY (Twitter) - Jun 26, 2023
- |||||||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P3 trial: A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet (clinicaltrials.gov) - Jun 26, 2023
P3, N=600, Not yet recruiting, Sponsor: LEO Pharma
- | Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world efficacy of adjunctive calcipotriene/betamethasone dipropionate foam for recalcitrant psoriatic lesions on the scalp or lower legs with biologic therapy. (Pubmed Central) - Jun 23, 2023
The Dermatology Life Quality Index and the nine-item Treatment Satisfaction Questionnaire for Medication questionnaire revealed improved life quality and a high level of satisfaction, with only a few mild adverse effects reported. In conclusion, adjunctive topical Cal/BD foam might be an effective and safe option for patients with recalcitrant lesions on the scalp and lower legs despite biologics use.
- || Review, Journal: Updated Review on Treatment of Atopic Dermatitis. (Pubmed Central) - Jun 19, 2023
We begin with topical treatments such as corticosteroids and calcineurin inhibitors and subsequently address the latest systemic treatments, such as Janus kinase inhibitors (upadacitinib, baricitinib, abrocitinib, gusacitinib) and interleukin (IL) inhibitors, which have proven efficacious in AD, namely, dupilumab (IL-4 and IL-13), tralokinumab (IL-13), lebrikizumab (IL-13), and nemolizumab (IL-31). Given the large number of drugs available, we summarize the pivotal clinical trials for each drug, evaluate recent real-world experience in terms of safety and efficacy for purposes of compilation, and provide evidence to guide the optimal choice of therapy.
- clobetasol propionate topical / Generic mfg.
Comparison of Effectiveness of Topical Treatments for Atopic Dermatitis () - Jun 19, 2023 - Abstract #RAD2023RAD_109;
There is a lack of head-to-head trials for topical treatments for AD. Due to the tremendous burden of AD on patients' physical and mental health, there is a need for additional therapies.
- Adbry (tralokinumab) / LEO Pharma, AstraZeneca
A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany () - Jun 19, 2023 - Abstract #RAD2023RAD_101;
Due to the tremendous burden of AD on patients' physical and mental health, there is a need for additional therapies. Initial findings from the first 100 patients from TRACE in Germany showed that the majority of adult patients with moderate-to-severe AD treated with tralokinumab were biologic-na
- Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis () - Jun 19, 2023 - Abstract #RAD2023RAD_86;
P3
Initial findings from the first 100 patients from TRACE in Germany showed that the majority of adult patients with moderate-to-severe AD treated with tralokinumab were biologic-na Among targeted treatments for moderate-to-severe AD used without concomitant topical corticosteroids for 12 to 16 weeks, upadacitinib 30 mg remains the most efficacious therapy in this NMA, generally followed by abrocitinib 200 mg, upadacitinib 15 mg, dupilumab 300 mg, and lebrikizumab 250 mg or abrocitinib 100 mg.
- A CME virtual patient simulation activity evaluated the management of adults with atopic dermatitis () - Jun 19, 2023 - Abstract #RAD2023RAD_83;
- Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Early insights into the characteristics of tralokinumab patients in a real-world setting in the United States () - Jun 19, 2023 - Abstract #RAD2023RAD_76;
This study provides early insights into the characteristics of tralokinumab patients in a real-world setting. While many characteristics were similar between biologic-na
- || Eucrisa (crisaborole) / Pfizer, Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Review, Journal: Safety of topical medications in the management of pediatric atopic dermatitis: an updated systematic review. (Pubmed Central) - Jun 19, 2023
This review was limited to English-language publications and the variable safety reporting of trial investigators. Many newer medications were not included due to pooled adult and paediatric safety data that did not meet inclusion criteria.
- || Adbry (tralokinumab) / LEO Pharma, AstraZeneca, lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Review, Journal: Investigational anti IL-13 asthma treatments: a 2023 update. (Pubmed Central) - Jun 14, 2023
Other attempts to block or, at least limit, the impact of IL-13 in asthma, such as the use of protein-protein interaction modulators, kinase inhibitors, bispecific antibodies, or IL-13 peptide vaccines, are largely still in the preclinical stage of development, and it is difficult to predict whether they will reach clinical development. Nevertheless, since IL-13 directly affects airway contractility and is critical for mucus production and remodelling, and airflow limitation and mucus hypersecretion are commonly treatable features in asthma, we suggest including an anti-IL-13 drug before GINA step 5.
- | Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: Ixekizumab for brodalumab-induced articular involvement in psoriatic arthritis: beyond IL-17A inhibition. (Pubmed Central) - Jun 14, 2023
Nevertheless, since IL-13 directly affects airway contractility and is critical for mucus production and remodelling, and airflow limitation and mucus hypersecretion are commonly treatable features in asthma, we suggest including an anti-IL-13 drug before GINA step 5. No abstract available
- | lebrikizumab (LY3650150) / Roche, Almirall, Eli Lilly
Journal: Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. (Pubmed Central) - Jun 13, 2023
Additionally, lebrikizumab does not interfere with IL-13 clearance. Lebrikizumab has a different mode of action to both tralokinumab and cendakimab, possibly contributing to the clinical efficacy observed by lebrikizumab in Ph2b/3 AD studies.
- | Journal: Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany. (Pubmed Central) - Jun 12, 2023
The model included anti-IL17s (brodalumab, secukinumab, ixekizumab and bimekizumab), anti-TNFs (adalimumab, etanercept, certolizumab and infliximab), an anti-IL12/23 (ustekinumab), and anti-IL23s (risankizumab, guselkumab and tildrakizumab). Among the anti-IL-23s, risankizumab had the lowest cost per PASI100-responder in both France (
- || Nucala (mepolizumab) / GSK, Fasenra (benralizumab) / AstraZeneca, Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Review, Journal: Pathogenic helper T cells as the novel therapeutic targets for immune-mediated intractable diseases. (Pubmed Central) - Jun 12, 2023
Delgocitinib shows that JAK-associated signaling is essential for the inflammatory reaction in atopic dermatitis, one of the common allergic diseases...These include calcitonin gene-related peptide (CGRP), reactive oxygen species (ROS) scavenging machinery regulated by the Txnip-Nrf2-Blvrb axis, and myosin light chain 9 (Myl9), which interacts with CD69. This review provides an updated view of the recent research on treatment of allergic diseases and their cause: conventional and pathogenic Th2 cells.
- ||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Clinical, Real-world evidence, Real-world: Any mention on real world OSD for tralokinumab (Twitter) - Jun 10, 2023
- ||| #EAACI2023 Potentials - omalizumab, benralizumab, mepolizumab, tralokinumab - none are yet approved for ocular allergy however (Twitter) - Jun 9, 2023
- || Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Clinical, P2b data, Journal: Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial. (Pubmed Central) - Jun 9, 2023
P2b
Delgocitinib cream reduced itch, pain and other signs and symptoms in patients with CHE. This data correlated with clinician-reported outcomes, indicating that the HESD may be a useful assessment tool for CHE management.
- | Journal: Atopic Dermatitis in Childhood and Adolescence: Diagnosis and Treatment. (Pubmed Central) - Jun 9, 2023
This data correlated with clinician-reported outcomes, indicating that the HESD may be a useful assessment tool for CHE management. A combination of baseline therapy, reactive and proactive anti-inflammatory therapy, and systemic therapy as needed is the foundation of successful interdisciplinary treatment for atopic dermatitis.
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
Journal, IO biomarker: A CCR4 antagonist attenuates atopic dermatitis-like skin inflammation by inhibiting the recruitment and expansion of Th2 cells and Th17 cells. (Pubmed Central) - Jun 6, 2023
Here, we investigated the role of CCR4 in an AD mouse model induced by MC903, a TSLP inducer...We further confirmed that compound 22 diminished the expansion of Th2 cells and Th17 cells in the coculture of CD11c + dendritic cells and CD4 + T cells derived from the regional LNs of AD mice. Collectively, CCR4 antagonists may exhibit anti-allergic effects by inhibiting both the recruitment and expansion of Th2 cells and Th17 cells in AD.
- | Retrospective data, Journal: Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study. (Pubmed Central) - Jun 5, 2023
No notable safety issues were identified in this study. Overall, the present study revealed that the biologics show differences in their tendency to develop a loss of efficacy, and the factors that negatively impact the survival rate of biologics include the previous use of biologics, obesity, and PsA.
- | Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Journal, HEOR: Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. (Pubmed Central) - Jun 2, 2023
Overall, the present study revealed that the biologics show differences in their tendency to develop a loss of efficacy, and the factors that negatively impact the survival rate of biologics include the previous use of biologics, obesity, and PsA. No abstract available
- ||||| Corectim (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma
Enrollment closed: A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema (clinicaltrials.gov) - Jun 1, 2023
P3, N=513, Active, not recruiting, Sponsor: LEO Pharma
No abstract available Recruiting --> Active, not recruiting
- | Innohep (tinzaparin) / LEO Pharma
Journal: Single-Bolus Tinzaparin Anticoagulation in Extended Hemodialysis Session: a Feasibility Study. (Pubmed Central) - May 29, 2023
This study shows that anti-Xa levels stabilized rapidly after administration on tinzaparin for 8-hour hemodialysis. Administration of a single bolus tinzaparin at the start of an 8-hour dialysis session appeared effective, although dose adjustment may be required.
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Journal: Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement. (Pubmed Central) - May 27, 2023
The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.